NCT05848739
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentSapience Therapeutics
~130 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:ST316FOLFIRI regimen & bevacizumabFruquintinibLonsurf & bevacizumab
At a glance
Recruiting sites
0 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Measured over 3 years
Conditions
Where it's being run
11 sites across 11 statesAlabama1
California1
Colorado1
Louisiana1
Massachusetts1
Michigan1
New York1
North Carolina1
Study leadership
- Abi Vainstein-Haras · STUDY_CHAIR · CMO
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.03 years
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0